Caseware UK (AP4) 2023.0.135 2023.0.135 2024-05-312024-05-31falseThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.12023-05-17truefalsetrue SC769635 2023-05-16 SC769635 2023-05-17 2024-05-31 SC769635 2024-05-31 SC769635 2022-05-31 2023-05-16 SC769635 c:Director1 2023-05-17 2024-05-31 SC769635 d:CurrentFinancialInstruments 2024-05-31 SC769635 d:CurrentFinancialInstruments d:WithinOneYear 2024-05-31 SC769635 d:ShareCapital 2024-05-31 SC769635 d:RetainedEarningsAccumulatedLosses 2024-05-31 SC769635 c:OrdinaryShareClass1 2023-05-17 2024-05-31 SC769635 c:OrdinaryShareClass1 2024-05-31 SC769635 c:FRS102 2023-05-17 2024-05-31 SC769635 c:AuditExempt-NoAccountantsReport 2023-05-17 2024-05-31 SC769635 c:FullAccounts 2023-05-17 2024-05-31 SC769635 c:PrivateLimitedCompanyLtd 2023-05-17 2024-05-31 SC769635 e:PoundSterling 2023-05-17 2024-05-31 xbrli:shares iso4217:GBP xbrli:pure
Registered number: SC769635


MATRIX BIO LTD








UNAUDITED

FINANCIAL STATEMENTS

FOR THE PERIOD 17 MAY 2023 TO 31 MAY 2024

 
MATRIX BIO LTD
REGISTERED NUMBER: SC769635

BALANCE SHEET
AS AT 31 MAY 2024

2024
Note
£

  

Current assets
  

Debtors: amounts falling due within one year
 4 
224

Cash at bank and in hand
 5 
2,488

  
2,712

Creditors: amounts falling due within one year
 6 
(2,829)

Net current (liabilities)/assets
  
 
 
(117)

Total assets less current liabilities
  
(117)

  

Net (liabilities)/assets
  
(117)


Capital and reserves
  

Called up share capital 
 7 
1

Profit and loss account
  
(118)

  
(117)


Page 1

 
MATRIX BIO LTD
REGISTERED NUMBER: SC769635
    
BALANCE SHEET (CONTINUED)
AS AT 31 MAY 2024

The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the period in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




Mr C Mosedale
Director

Date: 17 February 2025

The notes on pages 3 to 5 form part of these financial statements.

Page 2

 
MATRIX BIO LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 MAY 2024

1.


General information

Matrix Bio Limited is a private company limited by share capital, registered in Scotland.
                                                                                                                                                                              The company's registration number is SC769635.
                                                                                                                                                                    The company's registered office and trading address is 272 Bath Street, Glasgow, Scotland, United Kingdom, G2 4JR.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Research and development

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives, which range from 3 to 6 years.
If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

 
2.3

Government grants

Grants are accounted under the accruals model as permitted by FRS 102. Grants relating to expenditure on tangible fixed assets are credited to profit or loss at the same rate as the depreciation on the assets to which the grant relates. The deferred element of grants is included in creditors as deferred income.
Grants of a revenue nature are recognised in the Statement of Income and Retained Earnings in the same period as the related expenditure.

 
2.4

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

Page 3

 
MATRIX BIO LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 MAY 2024

2.Accounting policies (continued)

 
2.5

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.6

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


Employees

The average monthly number of employees, including directors, during the period was 1.


4.


Debtors

2024
£


Prepayments
224

224



5.


Cash and cash equivalents

2024
£

Cash at bank and in hand
2,488

2,488



6.


Creditors: Amounts falling due within one year

2024
£

Other creditors
309

Accruals
2,520

2,829


Page 4

 
MATRIX BIO LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 MAY 2024

7.


Share capital

2024
£
Authorised


100 Ordinary shares of £0.01 each
1

Allotted, called up and partly paid


100 Ordinary shares of £0.01 each
1

On incorporation 100 Ordinary shares of £0.01 each were issued to Mr C Mosedale at par value.


 
Page 5